Advertisement

Zukunftsperspektiven der Neuroleptika

  • F. Müller-Spahn
  • H. Hippns
Conference paper
Part of the Tropon-Symposium book series (BAYERZNS, volume 2)

Zusammenfassung

Die Beurteilung der Zukunftsperspektiven der Neuroleptika (NL) muß zunächst einmal von einer Analyse der Nutzen-Nebenwirkungsbeziehung sowie des Wirkungsmechanismus auf der Basis bisher vorliegender Ergebnisse ausgehen. Die Überlegenheit von NL gegenüber Plazebo konnte in kontrollierten Studien sowohl in der Behandlung akuter psychotischer Symptome (Davis et al. 1983) als auch in der Prävention psychotischer Rezidive nachgewiesen werden (Carpenter et al. 1982; Pietzcker et al. 1986).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Albus M (1983) Biochemical and clinical investigations with regard to plus and minus symptomatology in schizophrenia. Comm VII. World Congress of Psychiatry 1983Google Scholar
  2. Alfredsson G, Harnryd C, Wiesel FA (1985) Effects of sulpiride and chlorpromazine on autistic and positive psychotic symptoms in schizophrenic patients: relationship to drug concentrations. Psychopharmacology 85: 8–13PubMedCrossRefGoogle Scholar
  3. Andreasen NC, Smith MR, Jacoby CG et al. (1982) Ventricular enlargement in schizophrenia: definition and prevalence. Am J Psychiatry 139: 292–296PubMedGoogle Scholar
  4. Arnt J, Christensen AV, Hyttel J, Larsen J-J, Svendsen O (1983) Effects of putative dopamine autoreceptor agonists in pharmacological models related to dopaminergic and neuroleptic activity. Eur J Pharmacol 86: 185–198CrossRefGoogle Scholar
  5. Baldessarini RJ, Davis JM (1980) What is the best maintenance dose of neuroleptics in schizophrenia? Psychiat Res 3: 115–122CrossRefGoogle Scholar
  6. Battegay R, Cotar B, Fleischhauer J, Rauchfleisch U (1977) Results and side effects of treatment with clozapine ( Leponex R ). Compr Psychiatry 18: 423–428PubMedCrossRefGoogle Scholar
  7. Beckmann H, Haas S (1980) High dose diazepam in schizophrenia. Psychopharmacology 71: 7982CrossRefGoogle Scholar
  8. Benkert O, Hippius H (1986) Psychiatrische Pharmakotherapie. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  9. Bleuler M (1972) Die schizophrenen Geistesstörungen im Lichte langjähriger Kranken- und Familiengeschichten. Thieme, StuttgartGoogle Scholar
  10. Boyer P (1983) Evaluation of the desinhibitory effect of some neuroleptics at low doses in controlled trials. Comm. VII. World Congress of Psychiatry 1983Google Scholar
  11. Brown R, Colter N, Corsellis JAN et al. (1986) Postmortem evidence of structural brain changes in schizophrenia. Arch Gen Psychiatry 43: 36–42PubMedCrossRefGoogle Scholar
  12. Carpenter W (1986) Early, targeted pharmacotherapeutic intervention in schizophrenia. J Clin Psychiatry 47 (5): 23–29PubMedGoogle Scholar
  13. Carpenter WT, Stephens HJ, Rey AC, Hanlon TE, Heinrichs DW (1982) Early intervention vs. continuous pharmacotherapy of schizophrenia. Psychopharmacol Bull 18: 21–23Google Scholar
  14. Ciompi L, Müller C (1976) Lebensweg und Alter der Schizophrenen. Eine katamnestische Langzeitstudie bis ins Senium. Springer, Berlin Heidelberg New YorkGoogle Scholar
  15. Corsini GU, Piccardi MP, Bocchetta A, Bernardi F, Del Zompo M (1981) Behavioral effects of apomorphine in man: Dopamine receptor implications. In: Corsini GU, Gessa GL (eds) Apomorphine and other Dopaminomimetics, vol 2: Clinical pharmacology. Raven Press, New York, pp 13–24Google Scholar
  16. Crow TJ (1980) Molecular pathology of schizophrenia: More than one disease process? Br Med J 280: 66–68PubMedCrossRefGoogle Scholar
  17. Csernansky JG, Holman CA, Hollister LE (1983) Variability and the dopamine hypothesis of schizophrenia. Schizophr Bull 9 (3): 325–328PubMedGoogle Scholar
  18. Dabbagh M, Stanley S, Gershon S (1985) New antipsychotic agents: clinical studies. In: Burrows GD, Norman TR, Davis B (eds) Antipsychotics. Elsevier, Amsterdam, pp 147–161Google Scholar
  19. Davis JM, Janicak P, Linden R, Moloney J, Pavkovic J (1983) Neuroleptics and psychotic disorders. In: Coyle JT, Enna SJ (eds) Neuroleptics: neurochemical, behavioral and clinical perspectives. Raven Press, New York, pp 15–64Google Scholar
  20. Delini-Stula A (1986) Neuroanatomical, neuropharmacological and neurobiochemical target systems for antipsychotic activity of neuroleptics. Pharmacopsychiatry 19: 134–139PubMedCrossRefGoogle Scholar
  21. Dieterle DM, Ackenheil M, Müller-Spahn F, Kapfhammer HP (1987) Zotepine a neuroleptic drug with a bipolar therapeutic profile. Pharmacopsychiatry [Special Issue I] 20: 52–57CrossRefGoogle Scholar
  22. Donaldson SR, Gelenberg AJ, Baldessarini RJ (1983) The pharmacologic treatment of schizophrenia: a progress report. Schizophr Bull 9 (4): 504–527PubMedGoogle Scholar
  23. Edwards J, Alexander JR, Alexander MS et al. (1980) Controlled trial of sulpiride in chronic schizophrenic patients. Br J Psychiatry 137: 522–529PubMedCrossRefGoogle Scholar
  24. Goldberg SC (1985) Negative and deficit symptoms in schizophrenia do respond to neuroleptics. Schizophr Bull 11: 453–456PubMedGoogle Scholar
  25. Goldstein MJ (1970) Premorbid adjustment, paranoid status, and patterns of response to phenothiazines in acute schizophrenia. Schizophr Bull 3: 24–37Google Scholar
  26. Goldstein MJ, Rodnick EH, Evans JR, May PRA, Steinberg MR (1978) Drug and family therapy in the after care treatment of acute schizophrenics. Arch Gen Psychiatry 35: 1169PubMedCrossRefGoogle Scholar
  27. Grabowski-Anden M, Anden NE (1983) Stimulation of postsynaptic DA2-Receptors produces jerks in reserpin-treated rats. J Pharm Pharmacol 35: 543–545CrossRefGoogle Scholar
  28. Gravem A, Bugge A (1981) Cis(Z)-clopenthixol and clopenthixol in the treatment of acute psychoses and exacerbations of chronic psychoses. Acta Psychiat Scand [Suppl] 294: 13Google Scholar
  29. Gravem A, Engstrand E, Guleng RJ (1978) Cis(Z)-clopenthixol in chronic psychiatric patients. Acta Psychiat Scand 58: 384–388PubMedCrossRefGoogle Scholar
  30. Harding CM, Brooks CW, Takamara A, Strauss JS (1982) What happens to chronic psychiatric patients as they grow older? The Vermont Story. NIMH-Conference, Bethesda, 1–8 June 1982Google Scholar
  31. Holden JMC, Hsu W, Itil TM et al. (1971) Predictor patterns in the management of therapy-resistant schizophrenia. Dis Nerv Syst 32: 260–268PubMedGoogle Scholar
  32. Hollister LE, Overall JE, Kimbell I et al. (1974) Specific indications for different classes of phenothiazines Arch Gen Psychiatry 30: 94–99Google Scholar
  33. Huber G, Gross G, Schüttler R (1979) Schizophrenie. Eine Verlaufs- und sozialpsychiatrische Langzeitstudie. Springer, Berlin Heidelberg New YorkGoogle Scholar
  34. Jackson JH (1959) The factors of insanities (1894). In: Selected Writings, vol 2. Staples, London, p 411Google Scholar
  35. Janke W (1965) Untersuchungen zur Frage von Wirkungsunterschieden von Fluphenazin nach erst- und mehrmaliger Applikation. Psychopharmacology 7 (5): 349–365CrossRefGoogle Scholar
  36. Jimerson DC, Kaminen DPM van, Post RM, Docherty JP, Bunney WE Jr (1982) Diazepam in schizophrenia: a preliminary doubleblind trial. Am J Psychiatry 139: 489–491PubMedGoogle Scholar
  37. Kane JM (1984) The use of depot neuroleptics: clinical experience in the United States. J Clin Psychiatry 45 (5): 5–12PubMedGoogle Scholar
  38. Kane JM, Rifkin A, Woerner M et al. (1983) Low dose neuroleptics in the treatment of outpatient schizophrenics: I. relapse rates preliminary results. Arch Gen Psychiatry 40: 893PubMedCrossRefGoogle Scholar
  39. Kapfhammer HP, Rüther E (1987) Depot-Neuroleptika. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  40. Kebabian JW, Caine DB (1979) Multiple receptors for dopamine. Nature 277: 93–96PubMedCrossRefGoogle Scholar
  41. Klein DF, Rosen B (1973) Premorbid asocial adjustment and response to phenothiazine treatment among schizophrenic inpatients. Arch Gen Psychiatry 29: 480–485PubMedCrossRefGoogle Scholar
  42. Kolakowska T, Williams AO, Ardern M, Reveley MA, Jambor K, Gelder MG, Mandelbrote BM (1985) Schizophrenia with good and poor outcome; I: early clinical features, response to neuroleptics and signs of organic dysfunction. Br J Psychiatry 146: 229–246PubMedCrossRefGoogle Scholar
  43. Leff J, Kuipers L, Berkowitz R, Eberlein-Fries R, Sturgeon D (1984) Psychosocial relevance and benefit of neuroleptic maintenance: experience in the United Kingdom. J Clin Psychiatry 45 (5): 43–49PubMedGoogle Scholar
  44. Linden R, Davis JM, Rubinstein R (1984) Antipsychotics in the maintenance treatment of schizophrenia. In: Stancer HC, Garfinkel PE, Rakoff VM (eds) Guidelines for the use of psychotropic drugs. MTP Press, LancasterGoogle Scholar
  45. Mackay AVP (1980) Positive and negative schizophrenic symptoms and the role of dopamine. Br J Psychiatry 137: 379–386PubMedCrossRefGoogle Scholar
  46. Marder SR, Putten T van, Mintz J, Lebell M, McKenzie J, Faltico G (1984) Maintenance therapy: new findings. In: Kane JM (ed) Drug maintenance strategies in schizophrenia. APA, WashingtonGoogle Scholar
  47. Matz R, Rick W, Oh D, Thompson H, Gershon S (1974) Clozapine — a potential antipsychotic agent without extrapyramidal manifestations. Curr Ther Res 16: 687–695PubMedGoogle Scholar
  48. Mielke DH, Gallant DM, Kessler C (1977) An evaluation of a unique new antipsychotic agent, sulpiride: effects on serum prolactin and growth hormone levels. Am J Psychiatry 134: 1371–1375PubMedGoogle Scholar
  49. Naber D, Wirz-Justice A, Kafka MS et al. (1981) Seasonal variations in the endogenous rhythm of dopamine receptor binding in rat striatum. Biol Psychiatry 16: 831–839PubMedGoogle Scholar
  50. Ortiz A, Gershon S (1986) The future of neuroleptic psychopharmacology. J Clin Psychiatry 47 (5): 3–11PubMedGoogle Scholar
  51. Pietzcker A (1978) Langzeitmedikation bei schizophrenen Kranken. Nervenarzt 49: 518–533PubMedGoogle Scholar
  52. Pietzcker A, Gaebel W, Köpcke W et al. (1986) A german multicenter study on the neuroleptic long-term therapie of schizophrenic patients. Peliminary Report. Pharmacopsychiatry 4 (19): 161–166CrossRefGoogle Scholar
  53. Quadbeck H (1985) In: Interdisziplinärer Workshop. Deidesheim 1985Google Scholar
  54. Robertson MM, Trimble MR (1982) Major tranquillizers used as antidepressants. J Affect Dis 4: 173–193PubMedCrossRefGoogle Scholar
  55. Rüther E (1978) Interaction of neuroleptics clozapine and haloperidol. In: Deniker P et al. (eds) Neuro-Psychopharmacology. Pergamon Press, OxfordGoogle Scholar
  56. Sedvall G, Alfredsson G, Bjerkenstadt L, Härnryd C, Wiesel FA (1983) Possible differential effects of sulpiride and chlorpromazine on plus and minus symptomatology in schizophrenia. Relationship to drug concentrations. Comm. VII. World Congress of Psychiatry 1983Google Scholar
  57. Severson J, Marcusson J, Winblad B et al. (1982) Age-correlated loss of dopaminergic binding sites in human basal ganglia. J Neurochem 39: 1623–1631PubMedCrossRefGoogle Scholar
  58. Sieberns S, Spechtmeyer H (1982) Cis(Z)-Clopenthixoldecanoat, ein nues Depotneuroleptikum. Int Pharmacopsychiat 17: 170–184Google Scholar
  59. Simpson GM, Lee JH, Shrivastava RK (1978) Clozapine in tardive dyskinesia. Psychopharmacology 56: 75–80PubMedCrossRefGoogle Scholar
  60. Shimomura K, Satoh H, Hirai O et al. (1982) The central anti-serotonin activity of zotepine, a new neuroleptic, in rats. Jpn J Pharmacol 32: 405–412PubMedCrossRefGoogle Scholar
  61. Sternberg E (1981) Verlaufsgesetzlichkeiten der Schizophrenie im Lichte von Langzeituntersuchungen bis zum Senium. In: Huber G (Hrsg) Schizophrenie. Stand and Entwicklungstendenzen der Forschung. Schattauer, Stuttgart New YorkGoogle Scholar
  62. Sulpizio A, Fowler PJ, Macko E (1978) Antagonism of fenfluramine-induced hyperthermia: a measure of central serotonin inhibition. Life Sci 22: 1439–1446PubMedCrossRefGoogle Scholar
  63. Sulser F (1984) Regulation and function of noradrenaline receptor systems in brain. Neuropharmacol 23: 255–261CrossRefGoogle Scholar
  64. Tamminga CA, Schaffer MH (1979) Treatment of schizophrenia with ergot derivatives. Psycho-pharmacology 66: 239–242Google Scholar
  65. Tamminga CA, Schaffer MH, Smith RC, Davis JM (1978) Apomorphine improves schizophrenic symptoms. Science 200: 567–568PubMedCrossRefGoogle Scholar
  66. Thai LJ, Horowitz SG, Duorkin B et al. (1980) Evidence for loss of brain (3H)-spiroperidol and (3H)-ADTN binding sites in rabbit brain with aging. Brain Res 192: 185–194CrossRefGoogle Scholar
  67. Uchida S, Honda F, Otsuka M, Satoh Y, Mori J, Ono T, Hitomi M (1979) Pharmacological study of 2-chloro-11-(2-dimethylaminoethoxy) dibenzo (b,t) thiepin (zotepine). A new neuroleptic drug. Arzneimittelforsch 29: 1588–1594PubMedGoogle Scholar
  68. Van der Velde CD (1976) Variability of schizophrenia. Reflection of a regulatory disease. Arch Gen Psychiatry 33: 489–496PubMedCrossRefGoogle Scholar
  69. Vaughn CE, Leff JP (1976) The influence of family and social factors on the course of psychiatric illness. Br J Psychiatry 129: 125PubMedCrossRefGoogle Scholar
  70. Williams AO, Reveley MA, Kolakowska T et al. (1985) Schizophrenia with good and poor outcome. II: Cerebral ventricular size and its clinical significance. Br J Psychiatry 146: 239–246PubMedCrossRefGoogle Scholar
  71. Wöller W, Tegeler J (1983) Späte extrapyramidale Hyperkinesen, Klinik — Prävalenz — Pathophysiologie. FortschrNeurol Psychiatr 51: 131–157PubMedCrossRefGoogle Scholar
  72. Woggon B (in Discussion group) (1986) Biochemical and molecular mechanisms of action of neuroleptics, alternatives to the classical dopamine hypothesis. Pharmacopsychiatry 19: 140–144CrossRefGoogle Scholar
  73. Woggon B, Kuny S (1983) Cis(Z)-Clopenthixol in der Behandlung der akuten Schizophrenien. Sonderdruck aus: Clopixol Symposium, Kopenhagen, 8.-9. September 1983Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • F. Müller-Spahn
  • H. Hippns

There are no affiliations available

Personalised recommendations